DK3472183T3 - Variant adeno-associerede virus og fremgangsmåder til anvendelse - Google Patents

Variant adeno-associerede virus og fremgangsmåder til anvendelse Download PDF

Info

Publication number
DK3472183T3
DK3472183T3 DK17734575.8T DK17734575T DK3472183T3 DK 3472183 T3 DK3472183 T3 DK 3472183T3 DK 17734575 T DK17734575 T DK 17734575T DK 3472183 T3 DK3472183 T3 DK 3472183T3
Authority
DK
Denmark
Prior art keywords
methods
associated viruses
variant adeno
adeno
variant
Prior art date
Application number
DK17734575.8T
Other languages
English (en)
Other versions
DK3472183T5 (da
Inventor
Joshua Dudman
Adam Hantman
Loren Looger
Kimberly Ritola
David Schaffer
Sarada Viswanathan
Dougal Gowanlock Robinson Tervo
Bum-Yeol Hwang
Alla Karpova
Original Assignee
Hughes Howard Med Inst
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hughes Howard Med Inst, Univ California filed Critical Hughes Howard Med Inst
Application granted granted Critical
Publication of DK3472183T3 publication Critical patent/DK3472183T3/da
Publication of DK3472183T5 publication Critical patent/DK3472183T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/015—Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6027—Vectors comprising as targeting moiety peptide derived from defined protein from viruses ssDNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
DK17734575.8T 2016-06-15 2017-06-15 Variant adeno-associerede virus og fremgangsmåder til anvendelse DK3472183T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662350361P 2016-06-15 2016-06-15
US201662404585P 2016-10-05 2016-10-05
PCT/US2017/037781 WO2017218842A1 (en) 2016-06-15 2017-06-15 Variant adeno-associated viruses and methods of using

Publications (2)

Publication Number Publication Date
DK3472183T3 true DK3472183T3 (da) 2023-11-06
DK3472183T5 DK3472183T5 (da) 2024-09-09

Family

ID=59258370

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17734575.8T DK3472183T5 (da) 2016-06-15 2017-06-15 Variant adeno-associerede virus og fremgangsmåder til anvendelse

Country Status (27)

Country Link
US (2) US10961282B2 (da)
EP (2) EP4268852A3 (da)
JP (2) JP7094277B2 (da)
KR (2) KR102522661B1 (da)
CN (2) CN116003532A (da)
AU (2) AU2017286652B2 (da)
BR (1) BR112018076090A2 (da)
CA (1) CA3028113A1 (da)
DK (1) DK3472183T5 (da)
EA (1) EA201990033A1 (da)
ES (1) ES2962611T3 (da)
FI (1) FI3472183T3 (da)
HR (1) HRP20231403T1 (da)
HU (1) HUE063755T2 (da)
IL (2) IL300981A (da)
LT (1) LT3472183T (da)
MA (1) MA44546B1 (da)
MX (2) MX2018015770A (da)
MY (1) MY190221A (da)
PH (1) PH12018502664A1 (da)
PL (1) PL3472183T3 (da)
PT (1) PT3472183T (da)
RS (1) RS64769B1 (da)
SG (1) SG11201811189RA (da)
SI (1) SI3472183T1 (da)
WO (1) WO2017218842A1 (da)
ZA (1) ZA201900278B (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11136557B2 (en) 2013-05-31 2021-10-05 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
FI3445773T3 (fi) 2016-05-13 2023-03-30 4D Molecular Therapeutics Inc Adenoassosioituneen viruksen kapsidimuunnoksia ja niiden käyttömenetelmiä
EP3490531A4 (en) * 2016-07-29 2020-06-03 The Regents of The University of California VIONS OF ADENO-ASSOCIATED VIRUS WITH CAPSIDE VARIANT AND METHODS OF USE THEREOF
CN110709511A (zh) 2017-08-28 2020-01-17 加利福尼亚大学董事会 腺相关病毒衣壳变体及其使用方法
AU2018350700A1 (en) 2017-10-16 2020-05-07 Vigeneron Gmbh AAV vectors
MX2021001336A (es) * 2018-07-31 2021-09-10 Univ Cornell Métodos de terapia génica para controlar la función de órganos.
WO2020068990A1 (en) 2018-09-26 2020-04-02 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
WO2021022208A1 (en) * 2019-08-01 2021-02-04 Kaplitt Michael G Targeted gene therapy to treat neurological diseases
WO2022011390A1 (en) * 2020-07-08 2022-01-13 Baylor College Of Medicine Gene therapy for stxbp1 encephalopathy
CN111825772B (zh) * 2020-07-30 2023-10-20 中国科学院精密测量科学与技术创新研究院 具有变异衣壳蛋白的腺相关病毒及其应用
TW202214864A (zh) 2020-08-06 2022-04-16 應用醫學研究基金會 用於藉基因療法治療諸如阿茲海默症之Ｔａｕ蛋白病變的病毒顆粒
EP4263575A1 (en) * 2020-12-16 2023-10-25 Children's Medical Research Institute Adeno-associated virus capsids and vectors
WO2022126188A1 (en) * 2020-12-16 2022-06-23 Children's Medical Research Institute Aav capsids and vectors
CA3222723A1 (en) 2021-06-17 2022-12-22 Florian DZIOPA Aav manufacturing methods
WO2023288184A2 (en) * 2021-07-14 2023-01-19 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for treating chronic pain and for retrograde transduction of neurons
IL310017A (en) 2021-07-14 2024-03-01 Meiragtx Uk Ii Ltd RETGC gene therapy
CA3225080A1 (en) 2021-07-14 2023-01-19 Anastasios GEORGIADIS Kcnv2 gene therapy
WO2023131811A2 (en) 2021-12-15 2023-07-13 Meiragtx Uk Ii Limited Polycistronic expression of gut peptides
TW202346600A (zh) * 2022-03-30 2023-12-01 高等教育聯邦系統 匹茲堡大學 用於將核酸遞送至視網膜神經節細胞和/或視網膜色素上皮細胞的腺相關病毒載體
WO2024059667A2 (en) * 2022-09-13 2024-03-21 Dyno Therapeutics, Inc. Capsid variants and methods of using the same
WO2024056902A2 (en) 2022-09-16 2024-03-21 Christopher Shaw Compositions and methods for treating neurological diseases
WO2024079665A1 (en) 2022-10-11 2024-04-18 Meiragtx Uk Ii Limited Nucleic acid regulatory elements for constitutive gene expression and methods of use
WO2024079655A1 (en) 2022-10-11 2024-04-18 Meiragtx Uk Ii Limited Chromatography methods for purification of aav capsids
WO2024079657A1 (en) 2022-10-11 2024-04-18 Meiragtx Uk Ii Limited Formulations for aav gene therapy
WO2024079661A1 (en) 2022-10-11 2024-04-18 Meiragtx Uk Ii Limited Atp7b gene therapy
WO2024079662A1 (en) 2022-10-11 2024-04-18 Meiragtx Uk Ii Limited Upf1 expression constructs
WO2024126696A1 (en) 2022-12-14 2024-06-20 King's College London Compositions and methods for treating neurological diseases
WO2024148179A2 (en) * 2023-01-05 2024-07-11 Emugen Therapeutics Llc Retro-aav and use in treating neurodegenerative diseases
WO2024148189A2 (en) * 2023-01-05 2024-07-11 Emugen Therapeutics Llc Neuronal promoters and uses thereof
WO2024161022A2 (en) 2023-02-03 2024-08-08 King's College London Compositions and methods for treating neurological diseases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US9233131B2 (en) * 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
WO2006119150A2 (en) * 2005-04-29 2006-11-09 Beth Israel Deaconess Medical Center Compositions and methods for targeting of viral vectors
US20090215879A1 (en) 2008-02-26 2009-08-27 University Of North Carolina At Chapel Hill Methods and compositions for adeno-associated virus (aav) with hi loop mutations
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
RS62795B1 (sr) * 2011-04-22 2022-02-28 Univ California Adeno-povezani virioni virusa sa varijantama kapsida i postupci za njihovu primenu
US9719992B2 (en) 2011-10-07 2017-08-01 Howard Hughes Medical Institute Genetically encoded biosensors
WO2013174760A1 (en) 2012-05-25 2013-11-28 Deutsches Krebsforschungszentrum Optimized aav-vectors for high transduction rates in dendritic cells
US9518980B2 (en) 2012-10-10 2016-12-13 Howard Hughes Medical Institute Genetically encoded calcium indicators
US9518996B2 (en) 2013-08-05 2016-12-13 Howard Hughes Medical Institute Fluorescent protein-based calcium integrators
EP3561062A1 (en) 2013-09-13 2019-10-30 California Institute of Technology Selective recovery
CN104592364B (zh) * 2013-10-30 2018-05-01 北京大学 定点突变和定点修饰的腺相关病毒、其制备方法及应用
GB201403684D0 (en) * 2014-03-03 2014-04-16 King S College London Vector
WO2015164757A1 (en) * 2014-04-25 2015-10-29 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
US10370432B2 (en) * 2014-10-03 2019-08-06 University Of Massachusetts Heterologous targeting peptide grafted AAVS
RU2727015C2 (ru) * 2014-11-21 2020-07-17 Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл Векторы aav, нацеленные на центральную нервную систему
US9644007B2 (en) 2014-12-23 2017-05-09 Howard Hughes Medical Institute Red genetically encoded calcium indicators and methods of use
FI3445773T3 (fi) 2016-05-13 2023-03-30 4D Molecular Therapeutics Inc Adenoassosioituneen viruksen kapsidimuunnoksia ja niiden käyttömenetelmiä
EP3490531A4 (en) * 2016-07-29 2020-06-03 The Regents of The University of California VIONS OF ADENO-ASSOCIATED VIRUS WITH CAPSIDE VARIANT AND METHODS OF USE THEREOF

Also Published As

Publication number Publication date
ZA201900278B (en) 2022-04-28
WO2017218842A1 (en) 2017-12-21
CN116003532A (zh) 2023-04-25
MX2024000505A (es) 2024-03-19
EP3472183A1 (en) 2019-04-24
HUE063755T2 (hu) 2024-01-28
MA44546A1 (fr) 2019-07-31
IL263719B1 (en) 2023-05-01
IL300981A (en) 2023-04-01
AU2021225247B2 (en) 2023-02-16
JP2022126759A (ja) 2022-08-30
MA44546B1 (fr) 2021-03-31
PL3472183T3 (pl) 2024-02-12
US20190300579A1 (en) 2019-10-03
US10961282B2 (en) 2021-03-30
EA201990033A1 (ru) 2019-06-28
ES2962611T3 (es) 2024-03-20
KR20190039930A (ko) 2019-04-16
KR20230054754A (ko) 2023-04-25
JP7094277B2 (ja) 2022-07-01
CN109641939B (zh) 2022-11-08
JP2019518793A (ja) 2019-07-04
BR112018076090A2 (pt) 2019-03-26
DK3472183T5 (da) 2024-09-09
CA3028113A1 (en) 2017-12-21
EP4268852A2 (en) 2023-11-01
EP3472183B1 (en) 2023-08-09
MY190221A (en) 2022-04-06
HRP20231403T1 (hr) 2024-02-16
AU2017286652A1 (en) 2019-01-24
KR102522661B1 (ko) 2023-04-18
SI3472183T1 (sl) 2023-11-30
US11939355B2 (en) 2024-03-26
SG11201811189RA (en) 2019-01-30
US20210230231A1 (en) 2021-07-29
EP4268852A3 (en) 2024-02-07
AU2021225247A1 (en) 2021-09-30
RS64769B1 (sr) 2023-11-30
PH12018502664A1 (en) 2019-10-07
IL263719A (en) 2019-01-31
PT3472183T (pt) 2023-11-16
AU2017286652B2 (en) 2021-10-07
MX2018015770A (es) 2019-08-29
LT3472183T (lt) 2023-09-25
IL263719B2 (en) 2023-09-01
CN109641939A (zh) 2019-04-16
FI3472183T3 (fi) 2023-11-03

Similar Documents

Publication Publication Date Title
DK3472183T5 (da) Variant adeno-associerede virus og fremgangsmåder til anvendelse
DK3684423T3 (da) Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf
DK3445773T3 (da) Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf
HK1246355A1 (zh) 腺相關病毒變體及其使用方法
DK3445388T3 (da) Materialer og fremgangsmåder til behandling af hæmoglobinopatier
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3653221T3 (da) Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
DK3390430T3 (da) Human immundefektvirus-antigener, vektorer, sammensætninger og fremgangsmåder til anvendelse deraf
DK3557998T3 (da) Sammensætninger, kompositioner og anvendelsesmetoder
DK3259597T3 (da) Pvrig-polypeptider og fremgangsmåder til behandling
DK3160470T3 (da) Analoger af pridopidin, fremstilling og anvendelse heraf
BR112016016289A2 (pt) heteroaris e usos dos mesmos
DK3198009T3 (da) Onkolytiske tumorvira og anvendelsesfremgangsmåder
DK3394065T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf
DK3551209T3 (da) Insulin-fc-fusioner og fremgangsmåder til anvendelse
DK3331879T3 (da) Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3305310T3 (da) Onkolytisk virusformulering og fremgangsmåde til fremstilling deraf
DK3310190T3 (da) Sammensætning til behandling af kød og anvendelse af denne
DK3562946T3 (da) Oncolytiske virusser og terapeutiske molekyler
DK3130669T3 (da) Ny bakteriophag og sammensætning omfattende denne
DK3490988T3 (da) Ny forbindelse og fremgangsmåde
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
DK3250550T3 (da) Sammensætninger og fremgangsmåder til virussensibilisering
DK3197556T3 (da) Sammensætning til forebyggelse og/eller behandling af allergisymptomer